At week 32 , the mean increase from baseline in FEV1 was 100 ml greater in patients receiving intravenous mepolizumab than in those receiving placebo ( P = 0.02 ) and 98 ml greater in patients receiving subcutaneous mepolizumab than in those receiving placebo ( P = 0.03 ) .